Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial

IMPORTANCE: Confirmation of long-term comparability between subcutaneous and intravenous trastuzumab is essential. OBJECTIVE: To evaluate efficacy and safety of subcutaneous trastuzumab compared with that of intravenous trastuzumab for patients with ERBB2 (HER2)–positive early breast cancer after 6...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Jackisch, Christian, Stroyakovskiy, Daniil, Pivot, Xavier, Ahn, Jin Seok, Melichar, Bohuslav, Chen, Shin-Cheh, Meyenberg, Christoph, Al-Sakaff, Nedal, Heinzmann, Dominik, Hegg, Roberto
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2019
Matèries:
Brief Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512301/
https://ncbi.nlm.nih.gov/pubmed/30998824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.0339
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars